📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-26 19:54
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
63 announcements match the current filters (relevance ≥ 5).
Neogen's JV Arm to Raise ₹76.80 Cr via Preferential Issue to Morita Investment
Neogen Chemicals announced that its step-down subsidiary, Neogen Morita New Materials Limited (NML), has approved a preferential allotment of 7,20,000 equity shares to Morita Investment Limited for ₹76.80 crore. The shares are priced at ₹1,066.66 each (including a ₹1,056.66 premium per share), giving Morita a 9.09% post-allotment equity stake. The capital infusion is tied to an existing Joint Venture Agreement executed on August 31, 2025, to build out the battery materials ecosystem. This transaction represents ~8.3% of Neogen's TTM revenue of ₹926 crore and ~9% of its net worth.
Confidence: HIGH
What changedMorita Investment Limited is subscribing to a 9.09% stake in Neogen Morita New Materials Limited for ₹76.80 crore via a preferential issue.
Why it mattersThe equity infusion cements the technical and commercial joint venture with Morita for EV battery chemical capabilities while directly capitalizing the subsidiary.
Issue size: Rs. 76,80,00,000Issue price per share: Rs. 1,066.66Number of shares issued: 7,20,000Post-allotment holding of Morita: 9.09%Fundraise vs TTM revenue: ~8.3%Fundraise vs Net Worth: ~9.0%
📅 Short termPositive sentiment driver as strategic partner capital confirms execution milestone on the Morita JV without diluting parent company equity.
📈 Long termValidates Neogen's long-term expansion into high-value lithium-ion battery chemicals and electrolytes alongside an established Japanese partner.
⚠ Risk flags
- Execution timeline of the battery chemicals capex
- Commercialization pace of domestic EV battery demand in India
Key Highlights
Preferential issuance of 7,20,000 equity shares approved at ₹1,066.66 per share
Aggregate fundraise of ₹76.80 crore into step-down subsidiary Neogen Morita New Materials
Morita Investment Limited (wholly owned subsidiary of Morita Chemicals Industries) to hold a 9.09% stake post-allotment
Transaction executes on the Joint Venture Agreement dated August 31, 2025
👀 What to Watch
Track the deployment of funds toward electrolyte/lithium battery materials capacity and watch for operational updates or commercial timelines in upcoming quarterly calls.
CRISIL Revises Outlook to 'Stable' from 'Negative' on ₹880 Cr Facilities Post ₹600 Cr QIP
CRISIL Ratings has revised its rating outlook on Neogen Chemicals Limited's bank loan facilities and NCDs to 'Stable' from 'Negative', reaffirming the long-term rating at CRISIL A- and short-term rating at CRISIL A2+. The revision covers ₹680 crore of bank loan facilities and ₹200 crore of NCDs for Neogen Chemicals, alongside ₹1,150 crore of facilities for its subsidiary Neogen Ionics Limited (reaffirmed at CRISIL BBB+/Stable). The upgrade in outlook is driven by the completion of a ₹600 crore QIP (representing ~65% of TTM revenue and ~70% of net worth), which significantly improves liquidity, facilitates debt reduction, and supports capex following post-fire operational recovery.
Confidence: HIGH
What changedCRISIL upgraded the credit outlook from 'Negative' to 'Stable' across parent Neogen Chemicals (CRISIL A-) and subsidiary Neogen Ionics (CRISIL BBB+).
Why it mattersThe outlook upgrade eliminates immediate downgrade risk, lowers borrowing friction, and reflects significant balance sheet strengthening following the ₹600 crore equity infusion.
Neogen Bank Facilities Rated: ₹ 680 CroreNeogen NCDs Rated: ₹ 200 CroreNeogen Ionics Facilities Rated: ₹ 1,150 CroreQIP Proceeds Cited: Rs 600 croreQIP vs TTM Revenue: ~64.8%
📅 Short termPositive sentiment driver as removal of the negative credit watch reassures debt and equity markets regarding liquidity and balance sheet solvency.
📈 Long termStrengthens capital structure, improves financial flexibility for executing large-scale expansions in battery chemicals and electrolytes, and accelerates post-fire recovery.
⚠ Risk flags
- Execution risks on large capex projects at subsidiary Neogen Ionics
- Pacing of organic plant reconstruction following the Dahej fire
Key Highlights
CRISIL revised outlook to 'Stable' from 'Negative' while reaffirming long-term rating at CRISIL A- on ₹680 crore bank facilities and ₹200 crore NCDs.
Subsidiary Neogen Ionics Limited's outlook also revised to 'Stable' from 'Negative' with long-term rating reaffirmed at CRISIL BBB+ on ₹1,150 crore facilities.
Revision supported by ₹600 crore QIP completion aimed at debt reduction and working capital funding.
CRISIL noted gradual operational stabilization after the Dahej fire incident and ongoing commissioning of key capex projects.
👀 What to Watch
Track the upcoming quarterly balance sheet to verify debt reduction from the ₹600 crore QIP proceeds and monitor execution updates on the Dahej plant rebuild and battery chemicals capex.
Neogen Chemicals Raises ~₹600 Cr via Maiden QIP, Oversubscribed 6.5x
Neogen Chemicals has completed its first-ever Qualified Institutions Placement (QIP), raising approximately ₹600 crore against strong demand of over 6.5x. The issue resulted in the allotment of 26,60,753 shares at ₹2,255 each, representing an issue price above the floor price of ₹2,189.73. The capital raised represents about 9.5% of its current market cap and nearly 82% of its total debt (₹736 crore). Proceeds will primarily be used for debt reduction and working capital to support its transition from capital deployment to commercial production in battery chemicals.
Confidence: HIGH
What changedNeogen successfully issued 26.61 lakh new equity shares to institutional investors, boosting its net worth and cash reserves by ~₹600 crore.
Why it mattersThe fundraise significantly de-leverages the company by potentially wiping out a major portion of its ₹736 crore debt, drastically lowering finance costs and expanding funding for EV battery materials capex.
Total amount raised: ~INR 600 croreIssue price per share: INR 2,255Floor price: INR 2,189.73Shares allotted: 26,60,753Fundraise vs Total Debt: ~81.5%Fundraise vs Market Cap: ~9.5%
📅 Short termStock sentiment is likely to remain supported by institutional demand and pricing above floor price, though equity dilution of ~8.9% will take effect immediately.
📈 Long termStrengthens balance sheet health considerably, positioning the company to fund working capital needs as commercial supply of lithium-ion battery electrolytes ramps up.
⚠ Risk flags
- Equity dilution of existing shareholders (~8.9% increase in share count)
- Execution risks in scaling up the new advanced battery materials facility
Key Highlights
Raised approximately ₹600 crore via maiden QIP, oversubscribed by more than 6.5x
Allotted 26,60,753 equity shares at ₹2,255 per share, at a premium to the floor price of ₹2,189.73
Expanded paid-up equity share capital from ₹27.38 crore to approximately ₹30.04 crore (equity dilution of ~8.9%)
Participation from marquee institutions including ADIA, ICICI Prudential MF, Invesco MF, Mirae Asset MF, and SBI Life Insurance
Proceeds designated for debt prepayment/repayment and long-term working capital
👀 What to Watch
Track the upcoming quarterly balance sheet to verify debt reduction figures and interest cost savings, alongside revenue ramp-up from its battery materials subsidiary.
Neogen Chemicals Raises ₹600 Cr via QIP at ₹2,255/Share
Neogen Chemicals has concluded its Qualified Institutions Placement (QIP), raising approximately ₹600 crore through the allotment of 26,60,753 equity shares at an issue price of ₹2,255 per share (premium of ₹2,245 over face value of ₹10). The issue price represents a premium over the SEBI floor price of ₹2,189.73. The fundraise equals roughly 9.4% of current market cap (₹6,387 Cr) and 64.8% of TTM revenue (₹926 Cr), significantly strengthening its balance sheet against existing total debt of ₹736 Cr. Total outstanding equity shares increased by 9.7% from 2,73,81,674 to 3,00,42,427.
Confidence: HIGH
What changedNeogen Chemicals allotted 26,60,753 new equity shares to institutional investors, raising ₹600 crore and expanding its equity base by 9.72%.
Why it mattersProvides substantial growth capital amounting to nearly 70% of Net Worth (₹853 Cr) to fund capex in battery chemicals and deleverage debt.
Total Issue Size: ₹5,99,99,98,015.00Issue Price per Share: ₹2,255Floor Price: ₹2,189.73Fundraise vs TTM Revenue: ~64.8%Fundraise vs Market Cap: ~9.4%Equity Dilution: 8.86% post-issue (9.72% expansion)
📅 Short termPositive sentiment from pricing above floor price and strong institutional participation from marquee funds, offset slightly by short-term equity dilution.
📈 Long termStructurally bolsters balance sheet flexibility to execute long-term revenue targets of ₹1,150 Cr by FY28 through battery chemicals and pharma CSM projects.
⚠ Risk flags
- Equity dilution of ~8.86% post-issue
- Execution and return-ratio dilution risks if raised capital is deployed slowly
Key Highlights
Allotted 26,60,753 equity shares at ₹2,255 each, aggregating to ₹5,99,99,98,015 (₹600 crore)
Issue price of ₹2,255 is higher than the SEBI floor price of ₹2,189.73 per share
Paid-up share capital expanded from 2,73,81,674 to 3,00,42,427 shares of ₹10 each (9.72% equity dilution)
Major allottees include ICICI Prudential, Invesco India, Mirae Asset, and SBI Life Insurance, each securing 13.33% of the issue
👀 What to Watch
Track the deployment of funds toward battery chemicals expansion, Dahej plant rebuild, and potential deleveraging from current debt levels of ₹736 crore.
Neogen Chemicals raises ₹600 Cr via QIP at ₹2,255/share, dilutes equity by 8.86%
Neogen Chemicals approved the allotment of 26,60,753 equity shares to Qualified Institutional Buyers at an issue price of ₹2,255 per share (floor price: ₹2,189.73). The total fundraise amounts to ₹599.99 Cr, which represents ~9.4% of its market capitalization (₹6,387 Cr) and ~70% of its net worth (₹853 Cr). Paid-up equity capital expands from 2.74 Cr shares to 3.00 Cr shares, causing an 8.86% equity dilution. Key allottees include ICICI Prudential, Invesco India, Mirae Asset, SBI Life Insurance, WhiteOak Capital, Axis MF, and Abu Dhabi Investment Authority.
Confidence: HIGH
What changedThe company completed its QIP offering, raising ₹600 Cr and increasing total outstanding equity shares from 2,73,81,674 to 3,00,42,427.
Why it mattersThe ₹600 Cr capital infusion provides significant liquidity against existing debt of ₹736 Cr, potentially de-leveraging the balance sheet and funding expansion into battery chemicals and Dahej rebuild.
Total fundraise: ₹5,99,99,98,015.00Issue price: ₹ 2,255 per Equity ShareFloor price: ₹ 2,189.73Fundraise vs Market cap: ~9.4%Equity dilution: 8.86%
📅 Short termNear-term listing of the newly allotted shares on BSE/NSE will expand the floating stock and provide a liquidity buffer.
📈 Long termStrengthens equity net worth significantly from ₹853 Cr, aiding future capital expenditure for lithium electrolyte capacities and improving debt-to-equity leverage.
⚠ Risk flags
- Equity dilution of ~8.86% impacting EPS in the near term
- Execution risks on planned capex deployment
Key Highlights
Allotment of 26,60,753 shares at ₹2,255 each (including ₹2,245 premium) raising ₹5,99,99,98,015
Issue price set at ₹2,255 per share, representing a premium over the regulatory floor price of ₹2,189.73
Paid-up equity share capital increases from ₹27.38 Cr to ₹30.04 Cr
Major marquee allottees include SBI Life Insurance, ICICI Prudential, and Abu Dhabi Investment Authority (5.33%)
👀 What to Watch
Track the upcoming quarterly balance sheet for debt reduction or utilization updates toward capex in battery chemicals and the Dahej plant rebuild.
Neogen Chemicals Raises ₹600 Cr via QIP Allotment at ₹2,255/Share
Neogen Chemicals has approved the allotment of 26,60,753 equity shares to Qualified Institutional Buyers at an issue price of ₹2,255 per share, raising approximately ₹600 crore. The issue price reflects a premium over the SEBI floor price of ₹2,189.73 per share. This fundraise expands the company's equity base from 2.74 crore shares to 3.00 crore shares, resulting in an equity dilution of approximately 8.86%. Major institutional participants include ICICI Prudential Funds, SBI Life Insurance, Invesco India, Mirae Asset, and the Abu Dhabi Investment Authority.
Confidence: HIGH
What changedThe company completed its QIP, issuing 26.61 lakh new shares to raise ₹600 crore and expanding its equity share capital base by 9.72%.
Why it mattersThe ₹600 crore capital infusion represents ~70% of current net worth (₹853 crore) and nearly matches existing debt (₹736 crore), providing strong balance-sheet flexibility to fund ongoing expansions in battery chemicals and organic rebuilds.
Total Amount Raised: ₹5,99,99,98,015.00Issue Price per Share: ₹2,255Floor Price: ₹2,189.73Dilution (% of post-issue equity): 8.86%Fundraise vs Net Worth: ~70.3%Fundraise vs Debt: ~81.5%
📅 Short termImmediate focus will be on listing of the newly allotted shares on NSE/BSE and trading liquidity impact post-allotment.
📈 Long termSubstantially strengthens the balance sheet, lowering debt-equity strain and funding growth plans to achieve the targeted ₹1,150 crore revenue by FY28 via electrolytes and specialty chemicals.
⚠ Risk flags
- Equity dilution of ~8.86% impacting EPS until capital is deployed productively
- Execution risks and timelines in commissioning battery chemical capacities and rebuilding Dahej SEZ
Key Highlights
Allotment of 26,60,753 equity shares of face value ₹10 each at an issue price of ₹2,255 per share
Total capital raised stands at ₹5,99,99,98,015 (~₹600 crore)
Issue price of ₹2,255 is higher than the SEBI floor price of ₹2,189.73
Paid-up share capital increases from ₹27.38 crore to ₹30.04 crore (8.86% equity dilution)
Key allottees include SBI Life Insurance (13.33%), ICICI Prudential MF (13.33%), Invesco India (13.33%), Mirae Asset (13.33%), and ADIA (5.33%)
👀 What to Watch
Track the deployment of funds toward battery chemicals capex or debt reduction in upcoming quarterly earnings calls and capital expenditure disclosures.
Neogen Chemicals Closes ₹600 Cr QIP at ₹2,255 Per Share
Neogen Chemicals has declared the closure of its Qualified Institutions Placement (QIP) on September 16, 2026. The Fund-Raising Committee approved the issue price at ₹2,255 per share (including a premium of ₹2,245) for 26,60,753 equity shares, raising approximately ₹600 crore. This fundraise represents ~9.7% of the company's market cap (₹6,161 Cr) and ~70% of its current net worth (₹853 Cr). The issue had opened on September 10, 2026, following prior board and shareholder approvals.
Confidence: HIGH
What changedThe company finalized the pricing and closed its QIP, securing commitments for 26,60,753 equity shares at ₹2,255 each.
Why it mattersThe ₹600 crore proceeds substantially strengthen the balance sheet against existing debt of ₹736 crore, providing liquidity for ongoing expansions in specialty and battery chemicals.
Issue price per share: ₹ 2,255Shares allotted: 26,60,753Total QIP proceeds: ~₹600 CrFundraise vs Market Cap: ~9.7%Fundraise vs Net Worth: ~70.3%
📅 Short termShare count will increase upon allotment, creating minor equity dilution, but the price of ₹2,255 is close to the prevailing market price of ₹2,302.40, indicating firm institutional interest.
📈 Long termSignificantly bolsters net worth and lowers net leverage, easing financing for the Dahej plant rebuild and lithium-ion battery chemicals ramp-up towards the FY28 target.
⚠ Risk flags
- Equity dilution of ~9.9% on post-issue equity base
- Execution risks tied to the deployment of proceeds in new battery chemicals capacity
Key Highlights
QIP issue period closed on September 16, 2026, after opening on September 10, 2026
Issue price set at ₹2,255 per equity share, including a premium of ₹2,245 per share
Allotment of 26,60,753 fully paid-up equity shares of face value ₹10 each
Total capital raised stands at approximately ₹600 crore
👀 What to Watch
Track the upcoming share allotment, listing notifications, and management commentary on capital deployment toward debt reduction or battery chemical capex.
Neogen Chemicals closes ₹600 Cr QIP at ₹2,255/share, issuing 26.6 lakh equity shares
Neogen Chemicals has concluded its Qualified Institutional Placement (QIP), raising approximately ₹600 Cr. The company approved the allotment of 26,60,753 equity shares of face value ₹10 at an issue price of ₹2,255 per share (including a premium of ₹2,245). The fundraise represents nearly 9.7% of its current market capitalization (₹6,161 Cr) and about 70% of its existing net worth (₹853 Cr). The issue officially closed on September 16, 2026, following its opening on September 10, 2026.
Confidence: HIGH
What changedNeogen Chemicals concluded its QIP offering, determining an issue price of ₹2,255 per share to issue 26.6 lakh shares to QIBs.
Why it mattersThe ~₹600 Cr infusion meaningfully strengthens the balance sheet relative to its ₹736 Cr debt, reducing leverage and providing growth capital for its electrolyte and lithium-salt expansions.
Shares issued: 26,60,753Issue price per share: ₹ 2,255Face value: ₹ 10Premium per share: ₹2,245Fundraise vs Market Cap: ~9.7%Fundraise vs Net Worth: ~70.3%
📅 Short termShort-term equity dilution of around 9.9% of existing shares will absorb into trading; pricing at ₹2,255 reflects strong institutional demand close to market price (₹2,302.4).
📈 Long termSubstantially deleverages the balance sheet or fully funds capex targets for FY27/FY28 without stressing debt ratios.
⚠ Risk flags
- Equity dilution of existing shareholders
- Execution risk on timely deployment into projected battery chemical growth assets
Key Highlights
QIP issue closed on September 16, 2026, following receipt of funds from eligible QIBs
Total of 26,60,753 fully paid-up equity shares approved for allotment
Issue price fixed at ₹2,255 per equity share, including a premium of ₹2,245 per share
Total capital raised stands at approximately ₹600 Cr
👀 What to Watch
Track the upcoming shareholding pattern filings to observe institutional entry and dilution, alongside management commentary on deployment towards debt reduction or battery chemical capex.
Neogen Chemicals Launches QIP with Floor Price of ₹2,189.73 Per Share
Neogen Chemicals has officially opened its Qualified Institutions Placement (QIP) on September 10, 2026. The Fund-Raising Committee set the floor price at ₹2,189.73 per equity share, representing a ~6% discount to its current market price of ₹2,329.0. The company may also offer an additional discount of up to 5% on the floor price as per SEBI regulations. Total dilution size and aggregate issue amount will be finalized upon pricing and closing.
Confidence: HIGH
What changedNeogen Chemicals opened its QIP issue for eligible Qualified Institutional Buyers on September 10, 2026.
Why it mattersThe proceeds will provide growth capital to strengthen the balance sheet (current debt stands at ₹736 Cr with D/E of 0.86) and fund ongoing expansions into battery chemicals and specialty segments.
Floor Price: ₹ 2,189.73Max permissible discount: 5%Relevant Date: September 10, 2026Current Market Price: Rs 2329.0
📅 Short termShort-term equity price movement is likely to align near the discovered issue price, with potential mild dilution pressure offset by fresh institutional liquidity.
📈 Long termFresh equity capital improves leverage metrics and supports long-term capex targets in lithium electrolytes and specialty chemicals, aiding revenue growth toward target figures.
⚠ Risk flags
- Equity dilution for existing shareholders
- Allocation and issue size details yet to be finalized
Key Highlights
QIP issue officially opened on September 10, 2026 following prior shareholder approval on August 21, 2026
Floor price set at ₹2,189.73 per equity share (face value ₹10 each)
Discretionary discount of up to 5% permitted on the floor price under SEBI ICDR Regulations
Floor price of ₹2,189.73 trades at a 5.98% discount to recent trading price of ₹2,329.0
👀 What to Watch
Track the upcoming exchange filing disclosing the final issue price, total number of shares allotted, capital raised, and key institutional participants.
Neogen Chemicals Launches QIP with Floor Price of ₹2,189.73 Per Share
Neogen Chemicals has officially launched its Qualified Institutional Placement (QIP) on September 10, 2026. The Fund-Raising Committee set the floor price at ₹2,189.73 per equity share, representing a modest discount of ~6% to the current market price of ₹2,329. The company may also offer an additional discount of up to 5% on the floor price as per SEBI regulations. While the total issue size was not disclosed in the launch notice, the proceeds are expected to support balance sheet de-leveraging (current debt of ₹736 Cr, D/E of 0.86) and ongoing capex plans.
Confidence: HIGH
What changedNeogen Chemicals formally opened its QIP offering and approved the preliminary placement document and floor price.
Why it mattersThe equity infusion will reduce Neogen's leverage (debt of ₹736 Cr vs net worth ₹853 Cr) and help fund its battery chemicals and Dahej rebuild expansion plans, though it will result in equity dilution.
QIP Floor Price: ₹ 2,189.73 per Equity ShareFace Value: ₹10 eachPermissible Discount: not more than 5%Floor Price vs Current Market Price: ~6.0% discount
📅 Short termStock price may converge near the final issue price in the coming days as institutional bidding concludes and shares are allocated.
📈 Long termStrengthens capital structure by bringing down debt-to-equity (0.86), providing the capital needed to pursue FY28 revenue targets of ₹1,150 Cr and battery chemical capacity expansions.
⚠ Risk flags
- Equity dilution for existing shareholders
- Issue size and end-use allocation specifics not disclosed in this filing
Key Highlights
QIP opened for subscription on September 10, 2026
Floor price fixed at ₹2,189.73 per equity share (face value ₹10)
Company may offer a discount of up to 5% on the floor price as per SEBI ICDR regulations
Relevant date for the issue determined as September 10, 2026
👀 What to Watch
Track the upcoming filing for final issue price, total dilution, and allocation list to institutional investors to gauge institutional demand and balance sheet impact.
Neogen's subsidiary transfers LiPF6 business to step-down unit for ₹245 Cr
Neogen Chemicals announced an internal restructuring where its wholly owned subsidiary, Neogen Ionics Limited (NIL), will transfer its Electrolyte Salt (LiPF6) undertaking to step-down subsidiary Neogen Morita New Materials Limited (NML). The transaction is structured as a slump sale on a going concern basis for a net consideration of ₹245 Crore. The transferred undertaking contributed ₹0 in revenue for FY26 and has a net worth of ₹155.52 Crore (19.05% of consolidated net worth). The transaction is expected to be completed on or before March 31, 2027.
Confidence: HIGH
What changedNeogen approved the transfer of its LiPF6 undertaking from subsidiary NIL to step-down subsidiary NML for ₹245 Crore.
Why it mattersConsolidates electrolyte salt manufacturing under dedicated entity NML to streamline battery chemicals operations, with zero net impact on consolidated financials.
Transfer consideration: ₹245 CroreNet worth of undertaking: ₹155.52 CroreShare of consolidated net worth: 19.05%Completion target: March 31, 2027
📅 Short termNeutral immediate impact since this is an internal group restructuring between 100% owned subsidiaries without third-party cash outflow.
📈 Long termAligns strategic focus on the lithium-ion battery chemicals portfolio, facilitating focused scaling and potential partner integration for LiPF6 salts.
⚠ Risk flags
- Execution timeline for commissioning and commercializing the battery chemicals facilities by March 2027
Key Highlights
Internal business transfer of electrolyte salt assets to NML for ₹245 Crore consideration
Transferred undertaking has a net worth of ₹155.52 Crore (19.05% of consolidated net worth)
Target completion date for the BTA execution and transfer is on or before March 31, 2027
Consolidates Neogen's specialized Electrolyte Salt (LiPF6) operations under the Morita joint venture entity
👀 What to Watch
Track the execution of the BTA and commercialization timeline of the LiPF6 electrolyte salt manufacturing operations under NML towards FY27.
34% Revenue Growth in Q1 FY27; Neogen Raises Guidance and Plans ₹600 Cr QIP
Neogen Chemicals reported a strong Q1 FY27 with consolidated revenue growing 34% YoY to ₹250 cr and PAT surging 67% to ₹17 cr. Management has raised its standalone FY27 revenue guidance to ₹950–1,050 cr, reflecting confidence in the ramp-up of battery chemicals and organo-lithium segments. The Board approved a ₹600 cr QIP to deleverage the balance sheet and fund future growth, which represents approximately 11.2% of the current market capitalization. The Dahej replacement plant is nearing completion with commercial production expected to start in Q2 FY27.
Confidence: HIGH
What changedNeogen has shifted from a capacity-building phase to a revenue-generation phase, evidenced by a significant guidance upgrade and the successful ramp-up of its battery materials vertical.
Why it mattersThe company is positioning itself as a primary domestic supplier for the Indian EV battery ecosystem, which is projected to grow to 92 GWh by 2027. The ₹600 cr fundraise will significantly strengthen the balance sheet (current D/E 0.86) for this expansion.
Q1 FY27 Revenue: ₹250 crQ1 PAT Growth (YoY): 67%Proposed QIP Fundraise: ₹600 crQIP vs Market Cap: ~11.2%Revised FY27 Revenue Guidance: ₹950–1,050 crNet Insurance Claim Receivable: ₹186 cr
📅 Short termThe stock may see positive momentum following the guidance upgrade and strong Q1 earnings. The market will focus on the pricing of the ₹600 cr QIP and the resumption of the Dahej plant.
📈 Long termNeogen's strategic pivot toward battery chemicals and its partnership with Morita (Japan) for non-FEOC compliant supply chains could lead to structural re-rating as the domestic EV battery market scales toward 200 GWh by 2032.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Equity dilution from the ₹600 cr QIP
- Execution risks in commissioning new battery chemical facilities
- Volatility in global lithium prices affecting raw material costs
Key Highlights
Consolidated revenue increased 34% YoY to ₹250 cr in Q1 FY27, driven by record organo-lithium and battery chemical sales.
EBITDA margins expanded by 260 basis points to 19.3%, resulting in a 53% YoY growth in EBITDA to ₹48 cr.
Board approved a fundraise of ₹600 cr via QIP to support long-term capital requirements and deleveraging.
Neogen Ionics (battery chemicals) generated ₹19 cr in Q1 FY27, already exceeding 50% of its entire FY26 revenue.
Standalone revenue guidance for FY27 revised upwards to a range of ₹950–1,050 cr from the previous ₹875–950 cr.
👀 What to Watch
Investors should monitor the commercial production commencement at the Dahej plant in Q2 FY27 and the progress of the ₹600 cr QIP. Key execution milestones to watch include the commissioning of the electrolyte plant in H1 FY27 and lithium electrolyte salts in H2 FY27.
Q1 FY27: 34% Revenue Growth; Board Approves Rs 600 Cr QIP for Battery Chemicals Expansion
Neogen Chemicals reported a strong Q1 FY27 with consolidated revenue growing 34% YoY to Rs 250.3 Cr and PAT surging 67% to Rs 17.1 Cr. The company is executing a massive Rs 1,795 Cr capex plan for battery materials, representing approximately 208% of its TTM revenue, with Rs 1,298 Cr already incurred. To fund this expansion and manage debt, the Board has approved a Rs 600 Cr QIP. While EBITDA margins improved to 19.3%, finance costs rose 64% YoY due to increased debt for ongoing projects.
Confidence: HIGH
What changedNeogen has transitioned from planning to heavy execution of its battery materials pivot, backed by a new Rs 600 Cr fundraise approval and the completion of the Dahej plant reconstruction.
Why it mattersThe massive capex (over 2x TTM revenue) into Lithium-ion battery materials could structurally re-rate the company if it successfully secures approvals from global cell manufacturers and manages its high interest burden.
Q1 FY27 Revenue (Consolidated): Rs 250.3 CrTotal Capex vs TTM Revenue: ~208%Proposed QIP Fundraise: Rs 600 CrFinance Cost Growth (YoY): 64%EBITDA Margin: 19.3%
📅 Short termThe stock may react positively to the 67% PAT growth and the clarity provided on the Dahej plant reconstruction and insurance recoveries.
📈 Long termThe company is betting heavily on the EV ecosystem; long-term value depends on the successful commissioning of the Rs 1,367 Cr Pakhajan facility by March 2027.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High finance costs (up 64% YoY) impacting net margins
- Execution risk on the large-scale Rs 1,795 Cr capex
- Geopolitical freight spikes affecting input costs
Key Highlights
Consolidated PAT increased 67% YoY to Rs 17.1 Cr in Q1 FY27 from Rs 10.3 Cr in Q1 FY26
Total Battery Materials project cost estimated at Rs 1,795 Cr, with Rs 1,298 Cr (72%) already spent
Board approved raising up to Rs 600 Cr through a Qualified Institutional Placement (QIP)
Neogen Ionics revenue grew to Rs 19 Cr in Q1 FY27 compared to Rs 5 Cr in Q1 FY26
Dahej Phase 1 project (Rs 428 Cr) is on track for completion by February 2027
👀 What to Watch
Investors should track the execution timeline of the Pakhajan Phase 2 facility (March 2027) and the pricing/dilution impact of the upcoming Rs 600 Cr QIP.
34% Revenue Growth in Q1 FY27; Neogen Approves Rs 600 Cr QIP for Rs 1,795 Cr Battery Capex
Neogen Chemicals reported a strong Q1 FY27 with consolidated revenue rising 34% YoY to Rs 250.3 cr and PAT increasing 67% to Rs 17.1 cr. The battery chemicals subsidiary, Neogen Ionics, showed significant traction, contributing Rs 19 cr in revenue compared to Rs 5 cr in the previous year. The company is executing a massive Rs 1,795 cr capex plan for battery materials, which is approximately 208% of its TTM revenue. To support this, the board has approved a fundraise of up to Rs 600 cr via QIP, representing about 11% of its current market capitalization.
Confidence: HIGH
What changedNeogen has transitioned from recovering from the Dahej fire incident to an aggressive expansion phase in the EV battery materials sector, supported by a major new fundraise approval.
Why it mattersThe Rs 1,795 cr capex is transformative, representing over 2x the company's current annual revenue, pivoting the business toward high-growth Lithium-ion battery components.
Q1 FY27 Consolidated Revenue: Rs 250.3 crConsolidated PAT Growth (YoY): 67%Total Battery Capex Budget: Rs 1,795 crCapex vs TTM Revenue: 208.2%Proposed QIP Fundraise: Rs 600 crQIP vs Market Cap: 11.0%
📅 Short termThe stock may react positively to the strong margin expansion and the clarity provided on the Dahej plant restart and the funding roadmap for expansion.
📈 Long termThe structural shift into the EV battery supply chain (electrolytes and salts) could significantly re-rate the company if the 32,000 MT electrolyte capacity is successfully commissioned by FY27.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High interest costs (up 64% YoY) due to increased debt for capex
- Execution risk associated with the large-scale Pakhajan project
- Geopolitical supply chain inflation impacting working capital
Key Highlights
Consolidated EBITDA grew 53% YoY to Rs 48.2 cr, with margins expanding by 260 bps to 19.3%
Total estimated project cost for Battery Materials (Phase 1 & 2) stands at Rs 1,795 cr, with Rs 1,298 cr already incurred
Board approved a fundraise of up to Rs 600 cr through a Qualified Institutional Placement (QIP)
Neogen Ionics revenue reached Rs 19 cr in Q1 FY27, surpassing 50% of its entire FY26 revenue in one quarter
Cumulative insurance recoveries for the Dahej fire incident reached Rs 164 cr, with trial runs for the rebuilt plant now underway
👀 What to Watch
Watch for the successful pricing and completion of the Rs 600 cr QIP and the commercial production commencement at the rebuilt Dahej plant. Monitor the execution timeline of the Pakhajan Phase 2 project, which is critical for the FY27-28 growth targets.
67% PAT growth in Q1 FY27; Neogen approves ₹600 Cr QIP for ₹1,795 Cr battery project
Neogen Chemicals reported a strong Q1 FY27 with consolidated revenue rising 34% YoY to ₹250 crore and PAT increasing 67% YoY to ₹17 crore. Growth was driven by record revenues in Organolithium and a sharp ramp-up in the Battery Chemicals subsidiary (Neogen Ionics), which earned ₹19 crore vs ₹5 crore YoY. To fund its massive ₹1,795 crore battery materials expansion, the board approved a ₹600 crore QIP. While finance costs rose 64% due to debt-funded capex, the completion of the Dahej plant reconstruction and 72% capex deployment to date signal a major scale-up phase.
Confidence: HIGH
What changedNeogen has successfully transitioned its battery materials segment from development to revenue generation while securing board approval for a major equity fundraise to deleverage the balance sheet.
Why it mattersThe ₹1,795 crore capex is over 2x the company's TTM revenue, indicating a massive structural shift in scale. Successful execution could significantly re-rate the company as a key player in the global EV battery supply chain.
Q1 FY27 Revenue: ₹250 crQ1 FY27 PAT Growth: 67% YoYTotal Battery Capex vs TTM Revenue: 208%Proposed QIP Fundraise: ₹600 crCapex Incurred to Date: ₹1,298 crNet Insurance Claim Receivable: ₹186 cr
📅 Short termThe stock is likely to react positively to the strong earnings beat and the clarity provided on the Dahej plant reconstruction and insurance recoveries.
📈 Long termThe company is positioning itself as a critical supplier for Lithium-ion batteries; long-term value depends on the successful ramp-up of the Pakhajan Phase 2 project by March 2027.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High finance costs (up 64% YoY)
- Debt-to-Equity ratio of 0.86
- Execution risk for large-scale battery chemical projects
Key Highlights
Consolidated Revenue grew 34% YoY to ₹250 crore in Q1 FY27.
PAT increased 67% YoY to ₹17 crore, despite finance costs rising 64% to support expansion.
Board approved a ₹600 crore fundraise via QIP, representing approximately 11% of current market capitalization.
Total Battery Materials project cost estimated at ₹1,795 crore, with ₹1,298 crore (72%) already incurred.
Neogen Ionics revenue reached ₹19 crore in Q1, nearly 50% of its entire FY26 revenue.
👀 What to Watch
Watch for the commencement of commercial production at the rebuilt Dahej plant and the commissioning of the 1,000 MTPA Lithium Electrolyte Salts capacity scheduled for H2 FY27.
₹600 Cr Fundraise Approved via QIP; Subsidiary Borrowing Limit Raised to ₹500 Cr
Neogen Chemicals has received board approval to raise up to ₹600 crore through a Qualified Institutional Placement (QIP) or other modes, representing approximately 11% of its current market capitalization. This capital infusion is significant as it represents nearly 70% of the company's TTM revenue of ₹862 crore, likely intended for its battery chemicals expansion. Additionally, the board set August 13, 2026, as the record date for the final dividend and approved increasing the borrowing limit of its subsidiary, Neogen Morita New Materials, to ₹500 crore. The company is targeting a revenue of ₹1,150 crore by FY28, and this fundraise is a critical step toward that trajectory.
Confidence: HIGH
What changedThe company has moved from planning to formal board approval for a major capital raise and has set the timeline for its annual shareholder proceedings and dividend payouts.
Why it mattersThe fundraise is substantial relative to the company's size (11% of market cap) and is essential for funding the high-growth battery chemicals business. The increased borrowing limit for the subsidiary suggests aggressive expansion plans in specialized materials.
Proposed Fundraise: ₹600 CrFundraise vs Market Cap: ~11%Subsidiary Borrowing Limit: ₹500 CrDividend Record Date: August 13, 2026TTM Revenue: ₹862 Cr
📅 Short termThe stock may see positive momentum due to the growth-oriented fundraise, though the actual QIP pricing will determine the extent of equity dilution.
📈 Long termThe capital will support Neogen's transition into the EV battery supply chain, which is central to its FY28 revenue target of ₹1,150 crore.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Equity dilution for existing shareholders due to QIP
- Increased leverage risk as subsidiary borrowing limits are raised to ₹500 crore
- Execution risk in the new battery chemicals segment
Key Highlights
Board approved raising up to ₹600 crore via QIP or other permissible securities.
Subsidiary Neogen Morita New Materials to increase borrowing powers up to ₹500 crore.
Record date for final dividend and remote e-voting eligibility set for August 13, 2026.
37th Annual General Meeting (AGM) scheduled for August 21, 2026.
Fundraise amount of ₹600 crore is approximately 70% of the TTM revenue of ₹862 crore.
👀 What to Watch
Monitor the announcement of the QIP floor price and the specific utilization plan for the ₹600 crore, particularly regarding the Lithium-ion battery chemicals segment. Investors should also track the progress of the Dahej plant rebuild, which is expected to resume in FY27.
₹600 Cr Fundraise Approved and ₹500 Cr Subsidiary Borrowing Limit Increase
Neogen Chemicals has approved an in-principle fundraise of up to ₹600 crore through QIP or other instruments, representing approximately 11% of its current market capitalization and 70% of its net worth. Additionally, its subsidiary Neogen Morita New Materials is increasing its borrowing limit to ₹500 crore to support expansion. The company has fixed August 13, 2026, as the record date for the final dividend of FY25-26. These moves signal a significant capital push, likely directed toward the company's battery chemicals and electrolyte business.
Confidence: HIGH
What changedThe company has transitioned from planning to formal board approval for a major ₹600 crore capital infusion and significantly expanded the debt capacity of its subsidiary.
Why it mattersThe fundraise is massive relative to the company's current net worth (70%), indicating a high-conviction expansion phase into specialty battery chemicals which is central to their FY28 revenue target of ₹1,150 crore.
Proposed Fundraise: ₹600 croreFundraise vs Net Worth: ~70.3%Subsidiary Borrowing Limit: ₹500 croreDividend Record Date: August 13, 2026TTM Revenue: ₹862 crore
📅 Short termThe stock may see positive momentum due to the growth signal, though the potential for equity dilution from the QIP may cap immediate gains depending on the issue price.
📈 Long termThis is a structural move to capitalize on the EV battery supply chain; successful deployment of ₹1,100 crore in combined new capital/debt could significantly re-rate the company's scale.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Equity dilution risk from the ₹600 crore fundraise
- Increased interest burden if subsidiary debt is fully utilized
- Execution risk in the high-tech battery chemicals segment
Key Highlights
Board approved raising up to ₹600 crore via QIP or other eligible securities to fund growth.
Subsidiary Neogen Morita New Materials to increase borrowing powers up to ₹500 crore.
Record date for final dividend and AGM voting eligibility set for August 13, 2026.
CNK & Associates appointed as Internal Auditors for the financial year 2026-27.
37th Annual General Meeting (AGM) scheduled for August 21, 2026.
👀 What to Watch
Watch for the specific pricing and timing of the ₹600 crore QIP, as well as management commentary during the AGM regarding the deployment of these funds into the Lithium-ion battery chemical segment.
₹600 Cr Fundraise Approved; Subsidiary Borrowing Limit Increased to ₹500 Cr
Neogen Chemicals has received in-principle board approval to raise up to ₹600 Cr through QIP or other equity instruments, representing approximately 11% of its current market capitalization. Simultaneously, its subsidiary Neogen Morita New Materials is seeking shareholder approval to increase borrowing limits to ₹500 Cr, indicating a major capital push for its battery chemicals business. The company also finalized its Q1 FY27 results and set August 13, 2026, as the record date for the FY26 final dividend. These moves align with the company's strategy to reach ₹1,150 Cr revenue by FY28.
Confidence: HIGH
What changedThe company has transitioned from strategic planning to formal board approval for a major capital raise and significantly higher debt capacity for its key subsidiary.
Why it mattersThe ₹600 Cr fundraise is massive relative to the company's current net worth of ₹853 Cr (~70%), providing the necessary liquidity to scale its high-margin battery chemicals and specialty segments.
Proposed Fundraise: ₹600 CrFundraise vs Market Cap: ~11%Subsidiary Borrowing Limit: ₹500 CrDividend Record Date: August 13, 2026TTM Revenue: ₹862 Cr
📅 Short termThe stock may see volatility as the market digests the potential equity dilution from the ₹600 Cr fundraise, though the growth signal is strong.
📈 Long termThis capital infusion is critical for Neogen to achieve its FY28 revenue target of ₹1,150 Cr and establish itself in the EV battery supply chain.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Equity dilution from the proposed ₹600 Cr issuance
- Increased consolidated leverage if subsidiary borrowing is fully utilized
- Execution risk in the new battery chemicals segment
Key Highlights
Board approved raising up to ₹600 Cr via QIP or other eligible securities to fund growth initiatives.
Subsidiary Neogen Morita New Materials to increase borrowing powers under Section 180(1)(c) to ₹500 Cr.
Record date for the final dividend of FY 2025-26 fixed as August 13, 2026.
37th Annual General Meeting (AGM) scheduled for August 21, 2026.
Appointment of CNK & Associates as Internal Auditor for the financial year 2026-27.
👀 What to Watch
Monitor the pricing and timing of the ₹600 Cr fundraise to assess equity dilution impact. Track the deployment of funds into the Lithium-ion battery chemical segment, which is the primary growth driver.
₹600 Cr Fundraise Approved; Record Date for Dividend Set for Aug 13, 2026
Neogen Chemicals has received board approval to raise up to ₹600 crore through various instruments, including a Qualified Institutional Placement (QIP). This proposed fundraise is significant, representing approximately 70% of the company's current net worth (₹853 Cr) and 11% of its market capitalization. Additionally, the company has fixed August 13, 2026, as the record date for its final dividend. Its subsidiary, Neogen Morita New Materials, is also seeking to increase its borrowing limit to ₹500 crore to support growth initiatives.
Confidence: HIGH
What changedThe company has formally initiated a large-scale capital raising process and established the timeline for its annual dividend payout and shareholder meeting.
Why it mattersThe ₹600 crore raise is a major capital event intended to fund the company's expansion into battery chemicals and lithium salts. The high magnitude relative to net worth suggests an aggressive growth phase but carries dilution risks for existing shareholders.
Proposed Fundraise: ₹600 croreFundraise vs Net Worth: ~70.3%Fundraise vs Market Cap: ~11.0%Subsidiary Borrowing Limit: ₹500 croreDividend Record Date: 13-Aug-2026
📅 Short termThe stock may react to the potential dilution from the ₹600 crore raise, though the dividend record date provides a minor positive anchor for yield-seeking investors.
📈 Long termThe successful deployment of ₹600 crore into the battery chemicals segment is critical for Neogen to achieve its FY28 revenue target of ₹1,150 crore.
⚠ Risk flags
- Equity dilution from the ₹600 crore fundraise
- Increased leverage risk if the subsidiary utilizes the full ₹500 crore borrowing limit
- Execution risk in the capital-intensive battery chemicals segment
Key Highlights
Board approved a fundraise of up to ₹600 crore via equity or other eligible securities.
Record date for the final dividend for FY 2025-26 is fixed as August 13, 2026.
Subsidiary Neogen Morita New Materials to increase borrowing powers up to ₹500 crore.
37th Annual General Meeting (AGM) scheduled for August 21, 2026.
CNK & Associates appointed as Internal Auditors for the financial year 2026-27.
👀 What to Watch
Investors should monitor the specific terms and pricing of the ₹600 crore fundraise, as it will lead to equity dilution. Watch for the Q1 FY27 results (released concurrently) to see if operational cash flows are improving alongside this capital requirement.
₹600 Cr Fundraise Approved and Subsidiary Borrowing Limit Increased to ₹500 Cr
Neogen Chemicals has received board approval to raise up to ₹600 crore through equity or other instruments, representing approximately 11% of its current market cap and 70% of its net worth. Additionally, its subsidiary Neogen Morita New Materials is seeking shareholder approval to increase borrowing limits to ₹500 crore. The company has also fixed August 13, 2026, as the record date for the final dividend of FY 2025-26. These financial moves align with the company's stated strategy to reach ₹1,150 crore revenue by FY28 through battery chemical expansion.
Confidence: HIGH
What changedThe company has transitioned from strategic intent to formal board approval for a ₹600 crore capital raise and significantly higher debt capacity for its subsidiary.
Why it mattersThe fundraise is massive relative to the company's ₹853 crore net worth (70%) and is essential for funding the high-growth battery chemicals business which is key to their FY28 revenue targets.
Fundraise amount: ₹600 CrFundraise vs Net Worth: ~70.3%Subsidiary borrowing limit: ₹500 CrRecord date: August 13, 2026Fundraise vs Market Cap: ~11.0%
📅 Short termThe market may focus on the potential equity dilution from the ₹600 crore issue, but the record date for the dividend provides a near-term anchor for shareholders.
📈 Long termThis capital infusion is a structural necessity for Neogen to scale its electrolyte and lithium salt capacity; successful execution could significantly re-rate the business as it pivots toward the EV supply chain.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Equity dilution from the ₹600 crore fundraise
- Increased leverage risk if subsidiary borrowing is fully utilized
- Execution risk in the new battery chemicals segment
Key Highlights
Board approved fundraising of up to ₹600 crore via QIP or other permissible modes
Subsidiary Neogen Morita New Materials to increase borrowing powers to ₹500 crore
Record date for final dividend and AGM eligibility set for August 13, 2026
37th Annual General Meeting scheduled for August 21, 2026
Appointment of CNK & Associates as Internal Auditors for the financial year 2026-27
👀 What to Watch
Monitor the pricing and timing of the ₹600 crore fundraise to assess equity dilution levels. Watch for specific capex deployment updates in the upcoming AGM on August 21, 2026, particularly regarding the Lithium-ion battery chemical segment.
